Induction chemotherapy for squamous cell carcinomas of the oral cavity: A cumulative meta-analysis

Lau, Ashley; Li, Kar-Yan; Yang, Wei‐En; Su, Yu‐xiong

doi:10.1016/j.oraloncology.2016.08.022

Cited by 35 publications

(29 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CT can prove effective in advanced stage OSCC, but there is not evidence to support its benefits as an induction treatment [1,4,10,16]. Moreover, drug-related adverse side effects and acquired MDR limit its efficacy.…”

Section: Nano-based Chemotherapymentioning

confidence: 99%

Nanomedicine, an emerging therapeutic strategy for oral cancer therapy

et al. 2018

View full text Add to dashboard Cite

Oral cavity and oropharyngeal carcinomas (oral cancer) represents a significant cause of morbidity and mortality. Despite efforts in improving early diagnosis and treatment, the 5-year survival rate of advanced stage of the disease is less than 63%. The field of nanomedicine has offered promising diagnostic and therapeutic advances in cancer. Indeed, several platforms have been clinically approved for cancer therapy, while other promising systems are undergoing exploration in clinical trials. With its ability to deliver drugs, nucleic acids, and MRI contrast agents with high efficiency, nanomedicine platforms offer the potential to improve drug efficacy and tolerability. The aim of the present mini-review is to summarize the current preclinical status of nanotechnology systems for oral cancer therapy. The nanoplatforms for delivery of chemopreventive agents presented herein resulted in significantly higher anti-tumor activity than free forms of the drug, even against a chemo-resistant cell line. Impressive results have also been obtained using nanoparticles to deliver chemotherapeutics, resulting in reduced toxicity both in vitro and in vivo. Nanoparticles have also led to improvements in efficacy of photodynamic therapies through the development of targeted magnetic nanoparticles. Finally, gene therapy using nanoparticles demonstrated promising results specifically with regards to inhibition of gene expression. Of the few in vivo studies that have been reported, many of these used animal models with several limitations, which will be discussed herein. Lastly, we will discuss several future perspectives in oral cancer nanoparticle-based therapy and the development of appropriate animal models, distinguishing between oral cavity and oropharyngeal carcinoma.

show abstract

Section: Nano-based Chemotherapymentioning

confidence: 99%

Nanomedicine, an emerging therapeutic strategy for oral cancer therapy

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Conflicting results have been reported by various randomised controlled clinical trials designed with different inclusion criteria to test different chemotherapeutic regimens; results from meta-analyses were also inconsistent ( Table 2). [3][4][5]9,10 The definitions of locally advanced cancer and therefore the population of patients included in these studies were heterogeneous, ranging from cT2N0 (>3 cm) to cT4N3. 3,4 TPF has been shown to be superior to PF in multiple clinical trials and this was also confirmed in a meta-analysis using individual patient data.…”

Section: Discussionmentioning

confidence: 99%

Can Neoadjuvant Chemotherapy before Definitive Surgery Improve Outcome in Operable Stage IVA Oral Cavity Cancers?

Cheung¹,

Ngan²,

Chow³

et al. 2018

Hong Kong J Radiol

View full text Add to dashboard Cite

Introduction: To report the outcome for patients with stage IVA oral cavity (OC) cancer treated by docetaxelcisplatin-5-fluorouracil (TPF) neoadjuvant chemotherapy (NC) and surgery. Methods: This retrospective cohort study involved 69 consecutive patients with squamous cell carcinoma (SCC) of the OC managed from April 2012 to April 2015. Eleven stage IVA patients were treated by TPF NC before surgery following tumour board assessment. Another 11 stage IVA patients from the same cohort who received upfront surgery and adjuvant treatment were identified as controls. Results: TPF NC was given to four (36.4%) patients with a marginally resectable tumour and seven (63.6%) to prevent rapid clinical progression while awaiting definitive surgery. The median age at treatment was 55 (range, 32-65) years. A median of three (range, 3-4) cycles of NC were given. NC was well tolerated; grade 3 or 4 neutropenia or anaemia were observed in one (9.1%) patient each. Clinical complete response (CR), partial response, stable disease and progressive disease were observed in one (9.1%), five (45.4%), three (27.3%) and two (18.2%) patients, respectively. Complete (R0) resection was achieved in 10 (90.9%) patients. One (9.1%) patient had pathological CR. Median follow-up period was 49.5 months. Overall survival was significantly improved with NC (hazard ratio 0.24, median survival not reached [NR] vs. 12 months, p = 0.022). Distant relapse-free survival was also significantly improved with NC (hazard ratio 0.24, NR vs. 9.5 months, p = 0.024). Locoregional control rates were not significantly different (66% with NC vs. 53% without NC, p = 0.191). Conclusion: The outcomes of our small cohort suggested that TPF NC given before surgery could improve overall and distant relapse-free survival in patients with stage IVA OC SCC.

show abstract

“…It is debatable whether our patient should be judged as resectable or non-resectable. Induction chemotherapy was reported to be ineffective for resectable OSCC ( 14 , 15 ). Standard therapy for non-resectable OSCC is CRT with high-dose CDDP ( 13 ), while induction chemotherapy with TPF therapy is also regarded as standard therapy in Europe ( 16 ).…”

Section: Discussionmentioning

confidence: 99%

Lateral retropharyngeal lymph node metastasis from squamous cell carcinoma of the upper gingiva: A case report

et al. 2017

View full text Add to dashboard Cite

Lateral retropharyngeal lymph node (LRPLN) is located between the internal carotid artery and the prevertebral muscles. Metastasis to the LRPLN is frequent in nasopharyngeal cancer, but is rare in oral cancer. The prognosis of patients with oral cancer with LRPLN metastasis is usually poor. The present study reported a patient with LRPLN metastasis from squamous cell carcinoma of the upper gingiva, who survived for >7 years. Docetaxel, cisplatin and fluorouracil (TPF) therapy was performed as induction chemotherapy and it was planned to subsequently conduct chemoradiotherapy or surgery. As the tumor only exhibited a transient response to TPF, surgery was selected. Postoperatively, only radiotherapy was performed and a favorable outcome was achieved.

show abstract

Induction chemotherapy for squamous cell carcinomas of the oral cavity: A cumulative meta-analysis

Cited by 35 publications

References 37 publications

Nanomedicine, an emerging therapeutic strategy for oral cancer therapy

Nanomedicine, an emerging therapeutic strategy for oral cancer therapy

Can Neoadjuvant Chemotherapy before Definitive Surgery Improve Outcome in Operable Stage IVA Oral Cavity Cancers?

Lateral retropharyngeal lymph node metastasis from squamous cell carcinoma of the upper gingiva: A case report

Contact Info

Product

Resources

About